復星醫藥(02196.HK)子公司擬732萬美元受讓Nova JV餘下49%股權
格隆匯6月9日丨復星醫藥(02196.HK)發佈公吿,2021年6月9日,公司控股子公司Fosun Pharma USA與關聯方Fosun Healthcare簽訂《權益購買協議》,Fosun Pharma USA擬出資732萬美元受讓Fosun Healthcare所持有的Nova JV 49%的股權。
Nova JV的主要資產為其所持有的控股子公司Novelstar pharmaceuticals INC.(註冊於美國特拉華州,以下簡稱“Novelstar”)的股權,Novelstar主要從事有競爭力的仿製藥及改良劑型新藥(505b(2))項目的研發,目前有10個重點在研項目,包括3個仿製藥項目、6個505b(2)項目和1個505b(1)項目。
本次投資完成後,集團持有Nova JV的股權比例將由51%增加至100%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.